Entera Bio (ENTX) Non-Current Debt (2017 - 2026)
Entera Bio (ENTX) recorded quarterly Non-Current Debt of $567000.0 in Q1 2026, up 44.27% on a QoQ basis from $393000.0 in Q4 2025, and up 10.1% year-over-year from $515000.0 in Q1 2025.
Entera Bio (ENTX) Non-Current Debt (2017 - 2026) Analysis & Trends
Entera Bio has disclosed Non-Current Debt across 3 years of filings, most recently posting $567000.0 for Q1 2026.
- Quarterly Non-Current Debt rose 10.1% year-over-year to $567000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $567000.0 (up 10.1% YoY) and the FY2025 annual result came in at $393000.0, changed N/A from the prior year.
- Non-Current Debt grew to $567000.0 in Q1 2026, from $393000.0 in the prior quarter.
- Over five years, Non-Current Debt peaked at $567000.0 in Q1 2026 and troughed at $393000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Entera Bio | 56.59 Mn | 52.45 Mn | - | 567,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 567,000.00 |
| Mar 31, 2026 | 567,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Dec 31, 2025 | 393,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Sep 30, 2025 | 527,000.00 |
| Jun 30, 2025 | 524,000.00 |
| Jun 30, 2025 | 524,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Mar 31, 2025 | 515,000.00 |
| Dec 31, 2017 | 3.89 Mn |
| Dec 31, 2017 | 3.89 Mn |